SynthesisThe Cochrane database of systematic reviews2006
Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS).
Synthesis in The Cochrane database of systematic reviews, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS).The Cochrane database of systematic reviews · 2012Pooled it
- Pooled it
- Chinese herbs in treatment of influenza: a randomized, double-blind, placebo-controlled trial.Respiratory medicine · 2010Trial
- Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era.Acta pharmacologica Sinica · 2023Review
- Advancing herbal medicine: enhancing product quality and safety through robust quality control practices.Frontiers in pharmacology · 2023Review
- Article
- Use of and attitudes towards herbal medicine during the COVID-19 pandemic: A cross-sectional study in Vietnam.European journal of integrative medicine · 2021Article
- Toxicity as prime selection criterion among SARS-active herbal medications.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Review
- Non-evidenced based treatment: An unintended cause of morbidity and mortality related to COVID-19.The American journal of emergency medicine · 2021Article
- Efficacy and Safety of Qingfei Paidu Decoction for Treating COVID-19: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2021Article
- Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection.Frontiers in pharmacology · 2021Review
- The Therapeutic Effect of Traditional Chinese Medicine on Inflammatory Diseases Caused by Virus, Especially on Those Caused by COVID-19.Frontiers in pharmacology · 2021Review
- Potential treatment methods targeting 2019-nCoV infection.European journal of medicinal chemistry · 2020Review
- The honeysuckle genome provides insight into the molecular mechanism of carotenoid metabolism underlying dynamic flower coloration.The New phytologist · 2020Article
- Role of Complementary and Alternative Medicine in Prevention and Treatment of COVID-19: An Overhyped Hope.Chinese journal of integrative medicine · 2020Article
- Traditional and complementary treatments do have a role to play in global health, but probably not in emerging pandemics.Advances in integrative medicine · 2020Article
- Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus.Planta medica · 2014Article
- Traditional chinese medicine diagnosis "yang-xu zheng": significant prognostic predictor for patients with severe sepsis and septic shock.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Emodin inhibits current through SARS-associated coronavirus 3a protein.Antiviral research · 2011Article
- Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils.Acta pharmacologica Sinica · 2010Article
Corrections and comments
- Updated by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome (SARS) is an acute respiratory disease, which first appeared in Foshan City, China on 22 December 2002. It was reported by some that Chinese herbs played an important role in the treatment of SARS patients.
objectivesTo evaluate the possible effectiveness and safety of Chinese herbs combined with Western medicines versus Western medicines alone for SARS patients. SEARCH STRATEGY: We searched the following electronic databases for reports of randomised controlled trials: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2005); MEDLINE (1966 to September 2005); EMBASE (1990 to December 2004); and Chinese Biomedical Literature (lssue 2, 2005). SELECTION CRITERIA: Randomized and quasi-randomized controlled trials of Chinese herbs combined with Western medicines versus Western medicines alone for diagnosed SARS patients were included. DATA COLLECTION AND ANALYSIS: Two authors independently extracted the data from each trial. We extracted dichotomous and continuous data with 95% confidence intervals (CI). For dichotomous data, relative risk (RR) was used. For continuous data, we calculated weighted mean differences (WMD). Overall results were calculated based on the random effects model if heterogeneity existed between studies. If no heterogeneity was detected between the studies, we used the fixed effects model. Using the Z score and the chi square statistic with significance being set at p < 0.05 tested heterogeneity. MAIN
resultsWe finally included twelve randomized controlled trials and one quasi-randomized controlled trial. A total of 654 SARS patients and 12 Chinese herbs were identified. We did not find Chinese herbs combined with Western medicines decreased morbidity versus Western medicines alone. Two herbs may improve symptoms. Five herbs may improve lung infiltrate absorption. Four herbs may decrease the dosage of corticosteroids. Three herbs may improve the quality of life of SARS patients. One herb may shorten the length of stay in hospital. Only two trials reported adverse events. AUTHORS'
conclusionsChinese herbs combined with Western medicines made no difference in decreasing morbidity versus Western medicines alone. It is possible that Chinese herbs combined with Western medicines may improve symptoms, quality of life, and lung infiltrate absorption and decrease the corticosteroid dosage for SARS patients. The evidence is weak because of the poor quality of the included trials. Long-term of follow up of these included trials is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.